Free CME from PeerView


Emergency Medicine CME

PVI, PeerView Institute for Medical Education
Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
Geoffrey Barnes, MD, MSc
March 31, 2022
Medical Learning Institute, Inc.
Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs
John B. Buse, MD, PhD
March 25, 2022
Medical Learning Institute, Inc.
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
Kurt A. Schalper, MD, PhD
March 23, 2022
Medical Learning Institute, Inc.
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
Kurt A. Schalper, MD, PhD
March 22, 2022
Medical Learning Institute, Inc.
When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
Bradley J. Monk, MD, FACS, FACOG
March 22, 2022
PVI, PeerView Institute for Medical Education
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
Henry M. Kuerer, MD, PhD, FACs / Heather L. McArthur, MD, MPH
March 12, 2022
Medical Learning Institute, Inc.
Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now
Amit Bar-Or, MD, FRCPC / Daniel S. Reich, MD, PhD
February 26, 2022
PVI, PeerView Institute for Medical Education
Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It?
Herbert L. Bonkovsky, MD
February 25, 2022
Penn State College of Medicine
Hope Is on the Horizon: The Clinical Potential of Emerging Disease-Modifying Therapies for Managing Complement 3 Glomerulopathy
Carla M. Nester, MD, MSA, FASN
February 24, 2022
Medical Learning Institute, Inc.
Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC
February 22, 2022
Medical Learning Institute, Inc.
Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
Robert Dreicer, MD, MS, MACP, FASCO
February 19, 2022
Medical Learning Institute, Inc.
Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
Milind Javle, MD
February 16, 2022
Medical Learning Institute, Inc.
Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
Richard S. Finn, MD
February 15, 2022
Medical Learning Institute, Inc.
Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?
Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD
February 11, 2022
Erika Hamilton, MD
Medical Learning Institute, Inc.
Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies
Erika Hamilton, MD
January 19, 2022
William D. Tap, MD
Medical Learning Institute, Inc.
Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options
William D. Tap, MD
January 13, 2022
Michael Heinrich, MD
Medical Learning Institute, Inc.
Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
Michael Heinrich, MD
January 13, 2022
Medical Learning Institute, Inc.
Recent Advances and Novel Options in Depression: Reviewing the Evidence for GABA-Modulating Neuroactive Steroids for Major Depressive Disorder
Anita H. Clayton, MD
December 31, 2021
Medical Learning Institute, Inc.
Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors
Carlos M. de Castro, MD
December 31, 2021
PVI, PeerView Institute for Medical Education
A Closer Look at Telehealth for HIV: Best Practices for Patient Management in a Unique Era of Care
Christian B. Ramers, MD, MPH, AAHIVS
December 30, 2021
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Penn State College of Medicine
Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
December 30, 2021
Medical Learning Institute, Inc.
Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies
Petros Grivas, MD, PhD
December 29, 2021
Medical Learning Institute, Inc.
New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
Sara M. Tolaney, MD, MPH
December 28, 2021
Medical Learning Institute, Inc.
Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life
Lenard A. Adler, MD / Oren Mason, MD
December 23, 2021
Penn State College of Medicine
Disparities in the Management of Inflammatory Bowel Disease: Expert Perspectives on the Role of Race and Socioeconomic Factors on Care Delivery and Effectiveness
Sunanda Kane, MD
December 17, 2021
Medical Learning Institute, Inc.
Personalizing Treatment Decisions in HER2-Altered Breast Cancer: Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-Making
Joyce O’Shaughnessy, MD
December 10, 2021
Medical Learning Institute, Inc.
A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey
Suzanne Lentzsch, MD, PhD
December 10, 2021
Caron Jacobson, MD
Medical Learning Institute, Inc.
Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
Caron Jacobson, MD
December 10, 2021
Medical Learning Institute, Inc.
Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations
Naval Daver, MD
December 10, 2021
Medical Learning Institute, Inc.
Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
Grzegorz (Greg) Nowakowski, MD
December 10, 2021

Pages

Upcoming Live Events

Education Collections

More Education Collections

Recent CME Podcast

More Podcasts from PeerView